Skip to main content
Fig. 2 | Journal of Neurodevelopmental Disorders

Fig. 2

From: Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety

Fig. 2

Audiogenic seizure test. Audiogenic seizure severity was assessed in juvenile WT and KO mice after 5 days of treatment. The test was performed 60min after mice received the final dose. Both KO groups had increased seizure severity scores compared to each WT group with no effect of acamprosate treatment on seizure severity in either genotype (Wilcoxon rank sum test with exact probabilities calculated to determine pairwise group comparisons; FDR corrected). WT + SAL (n = 13), WT + Acamp (n = 13), KO + SAL (n = 15), KO + Acamp (n = 17); data shown are mean ± SEM; *p < 0.05

Back to article page